Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
03/2012
03/27/2012US8142772 Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
03/27/2012US8142771 Use of coccidian
03/27/2012US8142770 Drug comprising as the active ingredient proliferative vector containing survivin promoter
03/27/2012CA2603671C Insp163 polypeptides for the treatment or prevention of cancer and arthritis
03/27/2012CA2602730C Defective sindbis viral vectors
03/27/2012CA2584482C Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
03/27/2012CA2470245C Ifnar2 mutants, their production and use
03/27/2012CA2421087C Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy
03/27/2012CA2407423C Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
03/27/2012CA2378497C Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
03/27/2012CA2371922C Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
03/27/2012CA2282721C A transgenic coagulation factor xiii defective animal and its use for testing wound healing and bleeding
03/27/2012CA2230029C Multi-subtype fiv vaccines
03/22/2012WO2012037547A2 Methods and compositions for inhibiting autophagy for the treatment of fibrosis
03/22/2012WO2012037078A2 Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods
03/22/2012WO2012037043A2 Treatment of autoimmune inflammation using mir-155
03/22/2012WO2012036215A1 Inhibitor of hmgb protein-mediated immune response activation, and screening method
03/22/2012WO2012036214A1 Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
03/22/2012US20120071543 Formulations of diluted genetic material and methods for making same
03/22/2012US20120071415 Dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma)
03/22/2012US20120071407 Method of treating wounds
03/22/2012US20120071395 TREATMENT OF MAMMALIAN PHYSIOLOGICAL REACTION OF IgE ANTIBODIES PRESENT IN SAID MAMMAL UPON CONTACT WITH THE CORRESPONDEING ANTIGEN
03/22/2012US20120070892 DNA Virus MicroRNA and Methods for Inhibiting Same
03/22/2012US20120070437 Method of identifying compounds that bind baff-r
03/22/2012CA2811501A1 Inhibitor of hmgb protein-mediated immune response activation, and screening method
03/21/2012EP2431483A1 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
03/21/2012EP2431480A2 Methods and compositions for increasing the stress resistance of cells and organisms
03/21/2012EP2431467A2 Modulation of gene expression by oligomers targeted to chromosomal DNA
03/21/2012EP2431463A1 Test agent for visceral obesity and use thereof
03/21/2012EP2431405A1 Fine particles of crystalline polyol and method of preparing same
03/21/2012EP2431055A1 Conjugates of membrane translocating agents and pharmaceutically active agents
03/21/2012EP2430923A1 Compositions and methods for liver growth and liver protection
03/21/2012EP2429587A1 Organisms for the production of cyclohexanone
03/21/2012EP2429569A2 Treatment of eye diseases using encapsulated cells encoding and secreting a neuroprotective factor and/or an anti-angiogenic factor
03/21/2012EP2097110B1 Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (hcn) channels
03/21/2012EP1515988B1 Dna sequence and recombinant production of the grass pollen allergen phl p4
03/21/2012EP1506409B1 Assays for modulators of asparaginyl hydroxylase
03/21/2012EP1313853B1 Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody
03/21/2012EP1088077B2 Newcastle disease virus infectious clones, vaccines and diagnostic assays
03/21/2012EP0692972B2 Method for delivering beneficial compositions to hair follicles
03/21/2012CN1980699B Treatment methods utilizing albumin-binding proteins as targets
03/21/2012CN1946430B Therapeutic agent for treatment of cancer comprising human apolipoprotein (A) kringles LK68 or LK8 genes as effective ingredient, and method for treating cancer using the same
03/21/2012CN1554764B Recombinant mva virus, and the use thereof
03/21/2012CN102388139A Modulation of toll-like receptor 5 expression by antisense oligonucleotides
03/21/2012CN102387817A Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
03/21/2012CN102387784A Lyophilized recombinant vwf formulations
03/21/2012CN102382845A Method for producing porcine parvovirus antigen and its product
03/21/2012CN102382838A siRNA (small interfering Ribonucleic Acid) for suppressing PAR-1 (Proteinase Activated Receptor-1) gene expression and application thereof
03/21/2012CN102382837A SiRNA for inhibiting expression of PAR-1 gene and application thereof
03/21/2012CN102382836A siRNAs (small interfering ribonucleic acids) for suppressing expression of PAR-1 (proteinase activated receptor-1) genes and application thereof
03/21/2012CN102382835A siRNAs (small interfering ribonucleic acids) for suppressing expression of PAR-1 (proteinase activated receptor-1) genes and application thereof
03/21/2012CN102382834A SiRNA for inhibiting expression of PAR-1 gene and application thereof
03/21/2012CN102382833A siRNAs (small interfering ribonucleic acids) for suppressing expression of PAR-1 (proteinase activated receptor-1) genes and application thereof
03/21/2012CN102382832A SiRNA for inhibiting expression of PAR-1 gene and application thereof
03/21/2012CN102382831A shRNA for inhibiting Japanese encephalitis virus replication and infection and application thereof
03/21/2012CN102382828A PPP2R5C-siRNA991 for targeted inhibition of expression of PPP2R5C genes and multiplication of tumorous T cells and applications thereof
03/21/2012CN102382825A Human miR-1826 antisense nucleic acid and application thereof
03/21/2012CN102382824A Human miR-145 antisense nucleic acid and application thereof
03/21/2012CN102382823A Human miR-515-5p antisense oligod-eoxynucleotide and applications thereof
03/21/2012CN102382822A Cyclophilin gene inhibitor, preparation method and application thereof
03/21/2012CN102382187A FBXL15 protein fragment, coding gene thereof, and application of FBXL15 protein fragment and coding gene
03/21/2012CN102380099A Application of Wnt2 to preparation of medicament for inhibiting esophageal cancer
03/21/2012CN101805738B Peculiar p53 mutated protein-p53N236S of ALT tumor caused by progeria syndrome and application thereof
03/21/2012CN101591386B Polypeptide capable of inhibiting excitable and toxic damages and use thereof
03/21/2012CN101555469B High-efficiency recombined adenovirus containing ndrg2 gene and pharmic purpose thereof
03/21/2012CN101457226B Gene with nerve repair function, coding protein, interactive receptor and use thereof
03/21/2012CN101048502B Modified human hepatitis c virus genomic RNA having autonomous replicative competence
03/20/2012US8138329 siRNA targeting connective tissue growth factor (CTGF)
03/20/2012US8138328 Modulation of apolipoprotein (A) expression
03/20/2012US8138310 Chimeric CD154 polypeptides
03/20/2012US8138161 Using vector comprising nucleotide sequences which interfere with viral gene expression for prevention and treatment of hepatitis c viral infection; gene expression inhibition
03/20/2012US8138141 HMG1 antibody for treating inflammatory conditions
03/20/2012US8137969 Neural progenitor cells derived from embryonic stem cells
03/20/2012US8137965 Methods and compositions for tissue regeneration
03/20/2012US8137962 Compositions for treating cystic fibrosis
03/20/2012US8137947 Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small-molecule regulator
03/20/2012US8137934 Regeneration and neogenesis of retinal photoreceptor cell using Otx2 gene
03/20/2012US8137915 Genes involved in intestinal inflammatory diseases and use thereof
03/20/2012US8137904 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
03/20/2012US8137689 Transplant/implant device and method for its production
03/20/2012CA2549840C Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
03/20/2012CA2474801C Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
03/20/2012CA2424359C Implants with a phosphazene-containing coating
03/20/2012CA2410901C Methods and compounds for controlled release of recombinant parvovirus vectors
03/20/2012CA2379564C Structural protein of adeno-associated virus with modified chromatographic properties, its production and use
03/20/2012CA2278616C Adenoviruses having altered hexon proteins
03/20/2012CA2273622C Inhibition of nmda receptor signalling in reducing neuronal damage
03/20/2012CA2222000C Abundant extracellular products and methods for their production and use
03/15/2012WO2012032763A1 Vangl1 peptides and vaccines including the same
03/15/2012WO2012032497A1 Novel gene vaccination liposomes
03/15/2012WO2012032126A1 Use of a linear dna expression construct with covalently closed ends
03/15/2012WO2012032114A1 Use of a dna expression construct
03/15/2012WO2012031744A1 Chimeric antigen receptors with an optimized hinge region
03/15/2012WO2011159810A3 Compositions and methods for the treatment of atherosclerosis
03/15/2012WO2011146885A3 Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
03/15/2012WO2011135531A3 MEDICAL DEVICES FOR DELIVERY OF siRNA
03/15/2012WO2011118981A9 Novel use of erythroid differentiation regulator 1 as an agent for treating cancer
03/15/2012US20120065385 Dendritic cell co-stimulatory molecules
03/15/2012US20120065374 Dendritic cell co-stimulatory molecules
03/15/2012US20120065358 Biodegradable poly(beta-amino esters) and uses thereof
1 ... 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ... 870